Wells Fargo upgraded Travere Therapeutics (TVTX) to Overweight from Equal Weight with a price target of $27, up from $9.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics, CSL Vifor announce Swissmedic approval of FILSPARI
- Travere reports Swissmedic grants temporary marketing authorization for Filspari
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Travere Therapeutics initiated with an Outperform at Scotiabank
- Travere Therapeutics price target raised to $30 from $12 at Evercore ISI